diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5780diaendo-5780Research ArticleСтатьиArticlesОценка клинического применения Лантуса (инсулина гларгин) в практике работы эндокринологической службы МосквыOtsenka klinicheskogo primeneniya Lantusa (insulina glargin) v praktike raboty endokrinologicheskoy sluzhby MoskvyАнциферовМихаил БорисовичAntsiferovMikhail Borisovich-ДорофееваЛ ГDorofeevaL G-Эндокринологический диспансер Департамента здравоохранения г. Москвы20051506200582№2 (2005)3641Copyright © Анциферов М.Б., Дорофеева Л.Г., 20052005Анциферов М.Б., Дорофеева Л.Г.Antsiferov M.B., Dorofeeva L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5780

Несмотря на результаты DCCT и UKPDS , доказавшие необходимость адекватного гликемического контроля, большинство пациентов с СД 1 и 2 типа находятся в состоянии суб- и декомпенсации углеводного обмена. Внедрение в клиническую практику инсулина гларгин, имеющего по сравнению с НПХ-инсулином беспиковый профиль действия, более длительный период действия и простой алгоритм титрования дозы, возможно , позволит преодолеть барьеры, препятствующие достижению компенсации углеводного обмена у пациентов с СД 1 и 2 типа не только в условиях клинического исследования , но и в реальной клинической практике.

инсулин гларгинЛантуссахарный диабетэндокринологическая службаReferencesFritsche et al. Glimepiride combined with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine in patients with type 2 diabetes mellitus. A randomized control trial. Ann Intern Med 2003, 138: 952-959.Fritsche et al. Glimepiride combined with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine in patients with type 2 diabetes mellitus. A randomized control trial. Ann Intern Med 2003, 138: 952-959.Owens DR et al. Pharmacokinetics of 1251 -labeled insulin glargine in healthy men: comparison witn NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23:813-81 9.Owens DR et al. Pharmacokinetics of 1251 -labeled insulin glargine in healthy men: comparison witn NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23:813-81 9.Riddle MC et al. The Treat-To-Target Trial. Diabetes Core 2003, 26: 3080-3086.Riddle MC et al. The Treat-To-Target Trial. Diabetes Core 2003, 26: 3080-3086.Ryysy L et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorbtion are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49: 749-758.Ryysy L et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorbtion are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49: 749-758.Wright A et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes mellitus in the O.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25: 330-336.Wright A et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes mellitus in the O.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25: 330-336.Yki-Jarvinen H. Combination therapy with insulin and oral agents. Optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Met Res Rev 2002; 18 (Suppl 3): S77-81.Yki-Jarvinen H. Combination therapy with insulin and oral agents. Optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Met Res Rev 2002; 18 (Suppl 3): S77-81.Yki-Jarvinen H. Combination therapy with insulin in type 2 diabetes. Diabetes Care 2001, 24:758-767.Yki-Jarvinen H. Combination therapy with insulin in type 2 diabetes. Diabetes Care 2001, 24:758-767.Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long acting insulin glargin analogue. Eur J Clin Invest 2004; 34(6): 410 - 416.Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long acting insulin glargin analogue. Eur J Clin Invest 2004; 34(6): 410 - 416.Yki-Jarvinen H. et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargin compared with bedtime NPH insulin during combination insulin therapy in type 2 diabetes. HOE 901/3002 Study Group, Diabetes Care 2000, 23: 1 130-1136.Yki-Jarvinen H. et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargin compared with bedtime NPH insulin during combination insulin therapy in type 2 diabetes. HOE 901/3002 Study Group, Diabetes Care 2000, 23: 1 130-1136.Yki-Jarvinen H. et al. Comparison of bedtime insulin regimens in patients with in type 2 diabetes. A randomized control trial. Ann Intern MYki-Jarvinen H. et al. Comparison of bedtime insulin regimens in patients with in type 2 diabetes. A randomized control trial. Ann Intern M

The authors declare that there are no conflicts of interest present.